New data from two phase 3 studies found that in patients with relapsing forms of multiple sclerosis (MS), the new anti-CD20 monoclonal antibody drug, ublituximab, is associated with significant ...
Ultimate Growth Investing (UGI) Free Access offers some insights into what our subscribers receive in the Basic and Full Access. Limited access to market analysis, occasional trade alerts, and a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results